M
Marvin Garovoy
Researcher at University of Medicine and Dentistry of New Jersey
Publications - 11
Citations - 1971
Marvin Garovoy is an academic researcher from University of Medicine and Dentistry of New Jersey. The author has contributed to research in topics: Psoriasis & Efalizumab. The author has an hindex of 10, co-authored 11 publications receiving 1920 citations.
Papers
More filters
Journal ArticleDOI
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
Mark Lebwohl,Stephen K. Tyring,Tiffani K. Hamilton,Darryl Toth,Scott Glazer,Naji H. Tawfik,Patricia A. Walicke,Wolfgang Dummer,Xiaolin Wang,Marvin Garovoy,David M. Pariser +10 more
TL;DR: Efalizumab therapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe disease, and extending treatment from 12 to 24 weeks resulted in both maintenance and improvement of responses.
Journal ArticleDOI
Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
Michelle A. Lowes,Francesca Chamian,Maria Veronica Abello,Judilyn Fuentes-Duculan,Shao Lee Lin,Rachel Nussbaum,Inna Novitskaya,Henrietta Carbonaro,Irma Cardinale,Toyoko Kikuchi,Patricia Gilleaudeau,Mary Sullivan-Whalen,Knut M. Wittkowski,Kim A. Papp,Marvin Garovoy,Wolfgang Dummer,Ralph M. Steinman,James G. Krueger +17 more
TL;DR: A type of DC, which resembles murine "Tip-DCs" that can accumulate during infection, has proinflammatory effects in psoriasis through nitric oxide and TNF-alpha production, and can be an important target for suppressive therapies.
Journal ArticleDOI
Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Alice B. Gottlieb,James G. Krueger,Knut M. Wittkowski,Russell L. Dedrick,Patricia A. Walicke,Marvin Garovoy +5 more
TL;DR: At doses of 0.3 mg/kg or more per week, intravenous efalizumab produced significant clinical and histologic improvement in psoriasis, which correlated with sustained serum efalIZumab levels and T-cell CD11a saturation and down-modulation.
Journal ArticleDOI
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis
Alice B. Gottlieb,James G. Krueger,Ross Bright,Mark Ling,Mark Lebwohl,Sewon Kang,Steve R. Feldman,Mary C. Spellman,Knut M. Wittkowski,Hans D. Ochs,Paula Jardieu j,Robert Bauer k,Mark White j,Russell L. Dedrick,Marvin Garovoy +14 more
TL;DR: In this article, the authors explored the immunobiologic and clinical effects of treating moderate to severe psoriasis vulgaris with a single dose of humanized monoclonal antibody against CD11a (hu1124).
Journal ArticleDOI
The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
Kim A. Papp,Robert Bissonnette,James G. Krueger,Wayne Carey,David Gratton,Wayne Gulliver,Harvey Lui,Charles Lynde,Anna Magee,Daniel Minier,Jean P. Ouellet,Piyush M. Patel,Jerry Shapiro,Neil H. Shear,Susan M. Kramer,Patricia A. Walicke,Robert J. Bauer,Russell L. Dedrick,Sun Sook Kim,Mark White,Marvin Garovoy +20 more
TL;DR: Anti-CD11a antibody administered intravenously in 8 weekly doses of 0.3 mg/kg was well tolerated and induced clinical and histologic improvements in psoriasis.